Allyl methyl disulfide is a garlic-derived organosulfur disulfide found in volatile Allium oils and flavoring contexts. Current source-grounded evidence is strongest for identity, garlic-oil occurrence, flavor-use safety review, and a small preclinical pharmacology literature focused on liver-injury models and metabolism. That evidence remains animal or mechanistic rather than clinical, so the record should be read as constituent research and not a medical claim.
Aroma and practical use
- Use the recorded garlic-like, sulfury, pungent, sulfurous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2016 mouse study reported that AMDS lowered acetaminophen-driven ALT, AST, and LDH elevations, reduced liver malondialdehyde, restored antioxidant-enzyme activity, and suppressed IL-6 and TNF-alpha increases.
A 2016 mouse study reported that AMDS lowered acetaminophen-driven ALT, AST, and LDH elevations, reduced liver malondialdehyde, restored antioxidant-enzyme activity, and suppressed IL-6 and TNF-alpha increases.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2019 rat metabolism study reported that AMDS was mainly converted to allyl methyl sulfoxide and allyl methyl sulfone, with a short erythrocyte half-life for parent AMDS and much longer in-vivo half-lives for the oxidized metabolites.
A 2019 rat metabolism study reported that AMDS was mainly converted to allyl methyl sulfoxide and allyl methyl sulfone, with a short erythrocyte half-life for parent AMDS and much longer in-vivo half-lives for the oxidized metabolites.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 mouse and cell-model study reported that AMDS attenuated concanavalin-A-induced liver injury while suppressing M1 macrophage polarization and NLRP3 inflammasome activation.
A 2025 mouse and cell-model study reported that AMDS attenuated concanavalin-A-induced liver injury while suppressing M1 macrophage polarization and NLRP3 inflammasome activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
WHO/JECFA lists allyl methyl disulfide as having no safety concern at current levels of intake when used as a flavouring agent.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
That JECFA conclusion applies to flavor-use exposure, not to broad topical or supplement-style use claims.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No constituent-specific dermal limit or dedicated fragrance-safety dossier was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
Oxidative-stress and inflammatory-pathway modulation
Oxidative-stress and inflammatory-pathway modulation
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Sequential sulfur metabolism to AMS, AMSO, and AMSO2
Sequential sulfur metabolism to AMS, AMSO, and AMSO2
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- No human clinical trials specific to isolated allyl methyl disulfide were verified in this pass.
- Safety coverage is stronger for food-flavor exposure than for concentrated topical fragrance use.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.